Tuesday, November 30

Pfizer Announces Agreement to Produce COVID-19 Pill in 95 Countries

The American pharmaceutical company Pfizer announced on Tuesday that it will allow generic drug manufacturers to produce its experimental pill against COVID-19, among which there are eight of Latin America.

a release of the company explained that under an agreement signed with the group Medicines Patent Pool (MPP), backed by the UN, 95 low- and middle-income countries, representing 53% of the world’s population, will be able to manufacture the pill.

Belize, Bolivia, El Salvador, Guatemala, Haiti, Honduras, Nicaragua and Venezuela are the Latin American nations included in the list.

Pfizer said this month that its pill reduces the risk of hospitalization and death by nearly 90% in people with mild to moderate COVID-19, and has asked regulatory agencies in several countries to authorize its use as soon as possible.

Experts say the pill’s preliminary results are promising.

The agreement excludes some large countries that have suffered strong coronavirus outbreaks and has its peculiarities. A Brazilian pharmaceutical company could obtain a license to produce the drug and export it to other countries, but generic versions could not be manufactured for use in Brazil.

Doctors Without Borders criticized the agreement because it does not include countries like China, Argentina and Thailand, that have an established capacity to produce generic drugs.

“We must work to ensure that all people, regardless of where they live and their circumstances, have access to these advances,” said the CEO of Pfizer, Albert Bourla, it’s a statement.

Since the COVID-19 pandemic began last year, researchers around the world have worked tirelessly to develop a pill that can be easily swallowed at home to reduce symptoms, speed recovery, and protect against hospitalization.

Currently, most COVID-19 treatments must be administered intravenously or as injections.

Voice of america


Leave a Reply

Your email address will not be published. Required fields are marked *